2
项与 Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor(RegenxBio) 相关的临床试验A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
This long-term observational study is designed to follow subjects who, during another Clinical Study, received gene therapy treatment used to treat their Homozygous Familial Hypercholesterolemia (HoFH) disease. This study is intended to follow those subjects for up to 5 years since they received treatment to look for any long-term safety concerns. There is no investigational drug or therapy provided as part of this study.
AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)
This first-in-human study is intended to evaluate the safety and preliminary effectiveness of AAV (Adeno-associated virus)-based liver-directed gene therapy in the treatment of adults with Homozygous Familial Hypercholesterolemia (HoFH).
100 项与 Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor(RegenxBio) 相关的临床结果
100 项与 Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor(RegenxBio) 相关的转化医学
100 项与 Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor(RegenxBio) 相关的专利(医药)
100 项与 Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor(RegenxBio) 相关的药物交易